Private Trust Co. NA Has $2.60 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Private Trust Co. NA boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 6.0% in the fourth quarter, Holdings Channel reports. The firm owned 9,955 shares of the medical research company’s stock after purchasing an additional 560 shares during the period. Private Trust Co. NA’s holdings in Amgen were worth $2,595,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of AMGN. Capital Performance Advisors LLP acquired a new stake in Amgen during the 3rd quarter worth $25,000. Centricity Wealth Management LLC bought a new position in shares of Amgen during the 4th quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the 3rd quarter valued at approximately $29,000. Heck Capital Advisors LLC acquired a new stake in Amgen during the 4th quarter worth approximately $36,000. Finally, PrairieView Partners LLC boosted its holdings in shares of Amgen by 118.3% in the fourth quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock valued at $46,000 after buying an additional 97 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Down 0.2 %

Shares of AMGN opened at $305.82 on Friday. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The firm’s 50-day simple moving average is $279.97 and its 200 day simple moving average is $300.24. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market cap of $164.29 billion, a P/E ratio of 40.51, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.11%. Amgen’s dividend payout ratio is currently 126.09%.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Citigroup reaffirmed a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Piper Sandler boosted their target price on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $314.09.

Insider Transactions at Amgen

In other news, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP David M. Reese sold 8,711 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total value of $2,554,239.42. Following the sale, the executive vice president now owns 62,147 shares of the company’s stock, valued at approximately $18,222,743.34. This represents a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.